Ramp fiber, pair with water, prefer cooked sources first, and treat severe constipation as a clinical issue not a cue to double the powder
In women going through perimenopause or menopause, where metabolism often shifts, this can be particularly protective
Choose protein supplements without artificial sweeteners that trigger GI distress in sensitive individuals, and avoid products with added stimulants or appetite-suppressing ingredients
SURPASS-3 (vs
PT-141 Research# PT-141 completed the full drug development pathway: RECONNECT trials : Two Phase 3 pivotal trials in premenopausal women with HSDD demonstrated statistically significant improvements in sexual desire scores compared to placebo, with a meaningful increase in satisfying sexual events FDA approval : Approved June 21, 2019, as Vyleesi for HSDD in premenopausal women Male sexual dysfunction : Earlier trials explored PT-141 for male erectile dysfunction, though this indication was not pursued to approval Dose limitations : FDA label restricts use to no more than 8 doses per month and recommends against use in patients with uncontrolled hypertension or cardiovascular disease Post-marketing : Ongoing pharmacovigilance with established adverse event reporting The regulatory gap between MT-2 and PT-141 is the fundamental differentiator: PT-141 has undergone the rigorous efficacy and safety evaluation required for FDA approval, while MT-2 has not